Article Text

PDF

Treatment of acute retrolental fibroplasia by cryopexy.
  1. I Ben-Sira,
  2. I Nissenkorn,
  3. E Grunwald and
  4. Y Yassur

    Abstract

    Fifteen to 20% of premature infants weighing below 1500 g develop variable degrees of acute retrolental fibroplasia (RLF). Approximately 5% of those infants who develop RLF can be expected to become blind. A prospective study was carried out to evaluate if early cryopexy can prevent this blindness. The study showed that, among 533 infants admitted to the neonatal intensive care unit between July 1976 and December 1978, 55 had some degree of active RLF. In 18 eyes of 9 infants in whom the retinopathy progressed beyond active stage II cryopexy treatment was applied to the avascular retina. In all the treated eyes the active retinopathy regressed, and there were no complications due to the procedure. The long-term follow-up showed that in 15 eyes there was good vision and that the remaining 3 eyes had some impairment of vision but were not blind. These results suggest that cryotherapy may prove useful in treating premature infants with RLF who show progression of their active stage, without the danger of further visual loss or complete blindness.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.